Tivozanib is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase, mainly used for the treatment of advanced renal cell carcinoma (RCC). It exerts anti angiogenic effects by selectively inhibiting the VEGFR signaling pathway, with a long half-life and good tolerability.

1. Basic information of the drug

(1) Drug category: Tevozanib belongs to the second-generation VEGFR tyrosine kinase inhibitors (TKIs), targeting VEGFR-1/2/3.

(2) Research and Development Background: Developed by AVEO Oncology, it was first approved for the treatment of kidney cancer in the European Union in 2017.

(3) Dosage form specification: commonly 1.34mg hard capsules, recommended dosage is once daily oral administration.

2 Indications for Treatment

(1) Main indications: Used for the treatment of adult patients with advanced renal cell carcinoma, especially for patients who have received two or more systemic treatments in the past.

(2) Extended research: Clinical trials are currently underway for other solid tumors such as liver cancer and colorectal cancer.

3 mechanisms of action

(1) Target effect: Highly selective inhibition of tyrosine kinase activity of VEGFR-1/2/3, blocking angiogenesis signals.

(2) Treatment principle: By inhibiting tumor angiogenesis, cutting off tumor nutrient supply, and suppressing tumor growth and metastasis.

(3) Pharmacokinetic characteristics: The half-life is about 4-5 days, which can achieve sustained and stable blood drug concentration.

4 Clinical efficacy

(1) Progression free survival: Phase III trials have shown that PFS can be extended by approximately 1.5 months compared to other TKIs.

(2) Objective response rate: achieving an ORR of 18% in patients with refractory RCC.

(3) Tolerance advantage: Due to high selectivity, it reduces off target effects and has a lower incidence of adverse events.